FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

NICE Recommends Pfizer’s Breast Cancer Treatment

Jan. 2, 2018
A A

The National Institute for Health and Care Excellence (NICE) recommended Pfizer’s palbociclib for treatment of locally advanced or metastatic breast cancer.

NICE made the recommendation based on a review of a Pfizer submission concluding the drug was clinically effective based on a 666-patient clinical trial and a smaller 165-patient open-label study.

The drug is only recommended if Pfizer provides it with the discount agreed in the patient access scheme, the institute said.

View today's stories